The drug group exhibited significantly elevated expression of transforming growth factor β (TGF-β), hydroxyproline (HYP; which can indicate the degree of pulmonary fibrosis), Tumor Necrosis Factor α (TNF-α), and Interleukin 6 (IL-6) gene compared to the control group. This evidence concerns the gene TGFB1 and pulmonary fibrosis.